Top

Published in:

01-01-2019 | Review

Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer

Authors: Yang Liu, Yoshifumi Baba, Takatsugu Ishimoto, Masaaki Iwatsuki, Yukiharu Hiyoshi, Yuji Miyamoto, Naoya Yoshida, Rong Wu, Hideo Baba

Published in: Journal of Gastroenterology | Issue 1/2019

Abstract

Microbiome research is a rapidly advancing field in human cancers. Fusobacterium nucleatum is an oral bacterium, indigenous to the human oral cavity, that plays a role in periodontal disease. Recent studies have found that F. nucleatum can promote gastrointestinal tumor progression and affect the prognosis of the disease. In addition, F. nucleatum may contribute to the chemo-resistance of gastrointestinal cancers. This review summarizes recent progress in the pathogenesis of F. nucleatum and its impact on gastrointestinal cancer.

Arthur JC, Gharaibeh RZ, Muhlbauer M, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724.CrossRefPubMed

Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12.CrossRefPubMedPubMedCentral

Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014;146:1534–46.CrossRefPubMed

Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, et al. Infection and esophageal cancer. Ann N Y Acad Sci. 2014;1325:187–96.CrossRefPubMed

Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–72.CrossRefPubMed

Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444:1022–3.CrossRefPubMed

Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52:79–83.CrossRefPubMedPubMedCentral

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.CrossRefPubMed

Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:16.CrossRefPubMedPubMedCentral

10.

Garrett WS. Cancer and the microbiota. Science. 2015;348:80–6.CrossRefPubMedPubMedCentral

11.

Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med. 2016;22:458–78.CrossRefPubMedPubMedCentral

12.

Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352:535–8.CrossRefPubMedPubMedCentral

13.

Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906–15.CrossRefPubMed

14.

Bashir A, Miskeen AY, Hazari YM, et al. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol. 2016;37:2805–10.CrossRefPubMed

15.

Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. 2015;23:141–7.CrossRefPubMed

16.

Citron DM. Update on the taxonomy and clinical aspects of the genus fusobacterium. Clin Infect Dis. 2002;35:S22–7.CrossRefPubMed

17.

Signat B, Roques C, Poulet P, et al. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011;13:25–36.PubMed

18.

Dzink JL, Sheenan MT, Socransky SS. Proposal of three subspecies of Fusobacterium nucleatum Knorr 1922: Fusobacterium nucleatum subsp. nucleatum subsp. nov., comb. nov.; Fusobacterium nucleatum subsp. polymorphum subsp. nov., nom. rev., comb. nov.; and Fusobacterium nucleatum subsp. vincentii subsp. nov., nom. rev., comb. nov. Int J Syst Bacteriol. 1990;40:74–8.CrossRefPubMed

19.

Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.CrossRefPubMedPubMedCentral

20.

Kaplan CW, Lux R, Haake SK, et al. The Fusobacterium nucleatum outer membrane protein RadD is an arginine-inhibitable adhesin required for inter-species adherence and the structured architecture of multispecies biofilm. Mol Microbiol. 2009;71:35–47.CrossRefPubMed

21.

Bachrach G, Ianculovici C, Naor R, et al. Fluorescence based measurements of Fusobacterium nucleatum coaggregation and of fusobacterial attachment to mammalian cells. FEMS Microbiol Lett. 2005;248:235–40.CrossRefPubMed

22.

Fardini Y, Wang X, Temoin S, et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol. 2011;82:1468–80.CrossRefPubMedPubMedCentral

23.

Han YW, Ikegami A, Rajanna C, et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol. 2005;187:5330–40.CrossRefPubMedPubMedCentral

24.

Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRefPubMed

25.

Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.CrossRefPubMed

26.

Burgess DJ. Gene expression: colorectal cancer classifications. Nat Rev Cancer. 2013;13:380–1.CrossRefPubMed

27.

Flemer B, Warren RD, Barrett MP, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2018;67:1454–63.CrossRefPubMed

28.

Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.CrossRefPubMedPubMedCentral

29.

Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65:1973–80.CrossRefPubMed

30.

Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 2016;7:e200.CrossRefPubMedPubMedCentral

31.

Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1381–90.CrossRefPubMed

32.

Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53:517–24.CrossRefPubMed

33.

Eklof V, Lofgren-Burstrom A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;141:2528–36.CrossRefPubMedPubMedCentral

34.

Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66:1441–8.CrossRefPubMed

35.

Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23:2061–70.CrossRefPubMed

36.

Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–68.CrossRefPubMed

37.

Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016;22:557–66.CrossRefPubMedPubMedCentral

38.

Park HE, Kim JH, Cho NY, et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471:329–36.CrossRefPubMed

39.

Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Can Res. 2014;74:1311–8.CrossRef

40.

Lee DW, Han SW, Kang JK, et al. Association Between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–95.CrossRefPubMed

41.

Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206.CrossRefPubMedPubMedCentral

42.

Abed J, Emgard JE, Zamir G, et al. Fap2 Mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215–25.CrossRefPubMedPubMedCentral

43.

Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152:851–66.CrossRefPubMed

44.

Chen YY, Peng Y, Yu JH, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8:31802–14.PubMedPubMedCentral

45.

Yu YN, Yu TC, Zhao HZ, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget. 2015;6:32013–26.PubMedPubMedCentral

46.

Kumar A, Thotakura PL, Tiwary BK, et al. Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions. BMC Microbiol. 2016;16:84.CrossRefPubMedPubMedCentral

47.

Tang B, Wang K, Jia YP, et al. Fusobacterium nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells. PLoS One. 2016;11:e0165701.CrossRefPubMedPubMedCentral

48.

Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42:344–55.CrossRefPubMedPubMedCentral

49.

Saito T, Nishikawa H, Wada H, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679–84.CrossRefPubMed

50.

Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in colorectal carcinoma. JAMA Oncol. 2015;1:653–61.CrossRefPubMedPubMedCentral

51.

Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–15.CrossRefPubMedPubMedCentral

52.

Ye X, Wang R, Bhattacharya R, et al. Fusobacterium Nucleatum subspecies Animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res (Phila). 2017;10:398–409.CrossRefPubMed

53.

Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res. 2017;77:6777–87.CrossRefPubMedPubMedCentral

54.

Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome Fusobacterium Nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22:5574–81.CrossRefPubMed

55.

Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case–control study. Gut. 2018;67:120–7.CrossRefPubMed

56.

Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6:7209–20.PubMedPubMedCentral

57.

Yamamura K, Baba Y, Miyake K, et al. Fusobacterium nucleatum in gastroenterological cancer: evaluation of measurement methods using quantitative polymerase chain reaction and a literature review. Oncol Lett. 2017;14:6373–8.PubMedPubMedCentral

58.

Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443–8.CrossRefPubMedPubMedCentral

59.

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

60.

Castano-Rodriguez N, Goh KL, Fock KM, et al. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7:15957.CrossRefPubMedPubMedCentral

61.

Hsieh YY, Tung SY, Pan HY, et al. Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8:158.CrossRefPubMedPubMedCentral

62.

Wei ZL, Cao SG, Liu SL, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7:46158–72.PubMedPubMedCentral

63.

Yan X, Liu L, Li H, et al. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017;10:5031–46.CrossRefPubMedPubMedCentral

64.

Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(548–563):e516.

65.

Mehta RS, Nishihara R, Cao Y, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol. 2017;3:921–7.CrossRefPubMedPubMedCentral

66.

Pollock J, Glendinning L, Wisedchanwet T, et al. The madness of microbiome: attempting to find consensus “best practice” for 16S microbiome studies. Appl Environ Microbiol. 2018;84(7). pii: e02627–17. https://doi.org/10.1128/AEM.02627-17.

67.

Liu L, Tabung FK, Zhang X, et al. Diets that promote colon inflammation associate with risk of colorectal carcinomas that contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.04.030.CrossRefPubMedPubMedCentral

68.

Chen T, Li Q, Zhang X, et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum Pathol. 2018;79:93–101.CrossRefPubMed

69.

Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016;22:3227–33.CrossRefPubMedPubMedCentral

70.

Wang HF, Li LF, Guo SH, et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 2016;6:33440.CrossRefPubMedPubMedCentral

71.

Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66:462–70.CrossRefPubMed

72.

Suehiro Y, Sakai K, Nishioka M, et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem. 2017;54:86–91.CrossRefPubMed

73.

Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol. 2015;50:167–79.CrossRefPubMed

74.

Amitay EL, Werner S, Vital M, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis. 2017;38:781–8.CrossRefPubMed

75.

Guo SH, Wang HF, Nian ZG, et al. Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract. Sci Rep. 2017;7:10566.CrossRefPubMedPubMedCentral

76.

Zanzoni A, Spinelli L, Braham S, et al. Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins. Microbiome. 2017;5:89.CrossRefPubMedPubMedCentral

77.

Dix A, Vlaic S, Guthke R, et al. Use of systems biology to decipher host-pathogen interaction networks and predict biomarkers. Clin Microbiol Infect. 2016;22:600–6.CrossRefPubMed

Title: Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer
Authors: Yang Liu
Yoshifumi Baba
Takatsugu Ishimoto
Masaaki Iwatsuki
Yukiharu Hiyoshi
Yuji Miyamoto
Naoya Yoshida
Rong Wu
Hideo Baba
Publication date: 01-01-2019
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 1/2019
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-018-1512-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer

Correction to: Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis

Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page